Fundraising Fox
Tellus Therapeutics
Hillsborough, US · Founded 2018 · Delaware corporation · 1 known investors
Find your way into Tellus Therapeutics
Tellus Therapeutics is a biopharmaceutical company developing therapeutics. The about page primarily details the background of its board chairman.
Founders & leadership
Tellus Therapeutics was founded in 2018 by Eric Benner, M.D., Ph.D., Jason Kralic, Ph.D., and Simon Gregory, Ph.D..
EB
Eric Benner, M.D., Ph.D.Acting CSO and Co-founder
JK
Jason Kralic, Ph.D.CEO and Co-founder
SG
Simon Gregory, Ph.D.Scientific Co-Founder and Scientific Advisory Board Member
JE
Jason E. KarlicNamed on SEC filing
AM
Alex M. RuckdaeschelNamed on SEC filing
EJ
Eric J. BennerNamed on SEC filing
Board
CG
Chris GarabedianChairman of the Board
Investors · 1
Perceptive Xontogeny VenturereportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$18.1M disclosed across 3 rounds · 2019–2022
▶$16MraisedFeb 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$16MraisedFeb 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chris GarabedianDirector
- Jason E. KralicExecutive Officer, Director
- Eric J. BennerExecutive Officer, Director
- Fred CalloriDirector
- Offering amount
- $35M
- Amount sold
- $16M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$2MraisedJul 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJul 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric J. BennerExecutive Officer, Director
- Jason E. KralicExecutive Officer, Director
- Fred CalloriDirector
- Chris GarabedianDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- May 2021
- Incorporated
- Corporation, North Carolina, 2018
- Federal exemptions
- 06b
▶$75KraisedJan 2019 · 1 investors · Other Health CareRule 506(b)
▶$75KraisedJan 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jason E. KarlicExecutive Officer, Director
- Alex M. RuckdaeschelDirector
- Eric J. BennerExecutive Officer, Director
- Offering amount
- $75K
- Amount sold
- $75K
- First sale
- Jan 2019
- Incorporated
- Corporation, North Carolina, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
LatusLatus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise. The company operates from Philadelphia and Boston, serving the biotechnology and therapeutics industry.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Totus MedicinesTotus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology. The company focuses on oncology and other therapeutic areas for patients with currently incurable conditions.
Amicus TherapeuticsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Stylus MedicineStylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies working in the same space as Tellus Therapeutics.
In the news
Frequently asked questions
- What does Tellus Therapeutics do?
- Tellus Therapeutics is a biopharmaceutical company developing therapeutics. The about page primarily details the background of its board chairman.
- Who founded Tellus Therapeutics?
- Tellus Therapeutics was founded by Eric Benner, M.D., Ph.D., Jason Kralic, Ph.D., Simon Gregory, Ph.D. in 2018.
- Who are Tellus Therapeutics's investors?
- Tellus Therapeutics's investors include Perceptive Xontogeny Venture.
- How much funding has Tellus Therapeutics raised?
- Tellus Therapeutics has disclosed $18.1M raised across 3 rounds.
- Where is Tellus Therapeutics headquartered?
- Tellus Therapeutics is headquartered in Hillsborough, US.